3-(2,3-二氟苯基)-3-氧代丙酸乙酯 | 868611-68-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-(2,3-二氟苯基)-3-氧代丙酸乙酯
• 英文名称: ethyl 3-(2,3-difluorophenyl)-3-oxopropanoate
• CAS: 868611-68-1
• 化学式: C₁₁H₁₀F₂O₃
• 分子量: 228.195
• InChiKey: RPAWJNHLGNOQMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2918300090

反应信息

• 作为反应物：
  描述：

  3-(2,3-二氟苯基)-3-氧代丙酸乙酯 在 乙酸酐 、 potassium carbonate 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.17h， 生成 3,7-dihydro-3-ethyl-7-oxo-N-(pyridin-4-yl)-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide
  参考文献：
  名称：

  7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB₂ Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists

  摘要：

  Cannabinoid receptor agonists have gained attention as potential therapeutic targets of inflammatory and neuropathic pain. Here, we report the identification and optimization of a series of 7-oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide derivatives as a novel chemotype of selective cannabinoid CB2 receptor agonists. Structural modifications led to the identification of several compounds as potent and selective cannabinoid receptor agonists (20, hCB(2) K-i = 2.5 nM, SI = 166; 21, hCB(2) K-i = 0.81 nM, SI = 383; 38, hCB(2) K-i = 15.8 nM, SI > 633; 56, hCB(2) K-i = 8.12 nM, SI > 1231; (R)-58, hCB(2) K-i = 9.24 nM, SI > 1082). The effect of a chiral center on the biological activity was also investigated, and it was found that the (R)-enantiomers exhibited greater affinity at the CB2 receptor than the (S)-enantiomers. In 3,5-cyclic adenosine monophosphate assays, the novel series behaved as agonists, exhibiting functional activity at the human CB2 receptor.

  DOI：

  10.1021/jm300763w
• 作为产物：
  描述：

  2,3-二氟苯甲酸 、 magnesium bis(3-ethoxy-3-oxopropanoate) 在 carbonyldiimidazole 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 3-(2,3-二氟苯基)-3-氧代丙酸乙酯
  参考文献：
  名称：

  7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB₂ Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists

  摘要：

  Cannabinoid receptor agonists have gained attention as potential therapeutic targets of inflammatory and neuropathic pain. Here, we report the identification and optimization of a series of 7-oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide derivatives as a novel chemotype of selective cannabinoid CB2 receptor agonists. Structural modifications led to the identification of several compounds as potent and selective cannabinoid receptor agonists (20, hCB(2) K-i = 2.5 nM, SI = 166; 21, hCB(2) K-i = 0.81 nM, SI = 383; 38, hCB(2) K-i = 15.8 nM, SI > 633; 56, hCB(2) K-i = 8.12 nM, SI > 1231; (R)-58, hCB(2) K-i = 9.24 nM, SI > 1082). The effect of a chiral center on the biological activity was also investigated, and it was found that the (R)-enantiomers exhibited greater affinity at the CB2 receptor than the (S)-enantiomers. In 3,5-cyclic adenosine monophosphate assays, the novel series behaved as agonists, exhibiting functional activity at the human CB2 receptor.

  DOI：

  10.1021/jm300763w

文献信息

• Pyrimidinones. 1. 2-Amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-inducing antiviral agents
  作者：Harvey I. Skulnick、Sheldon D. Weed、Emerson E. Eidson、Harold E. Renis、Dale A. Stringfellow、Wendell Wierenga

  DOI：10.1021/jm00150a018

  日期：1985.12

  2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone. An analogue study incorporating a series of 2-amino-5-substituted-6-arylpyrimidinones revealed that the most potent interferon inducers were mono- and difluorophenyl analogues. These same analogues were also potent antiviral agents against Semliki Forest virus and herpes simplex type 1. In addition the monomethoxyphenyl analogues were potent antiviral agents but weak interferon

  发现2-氨基-5-溴-6-苯基-4（3H）-嘧啶酮具有干扰素诱导作用和抗病毒活性。包含一系列2-氨基-5-取代-6-芳基嘧啶酮的类似物研究表明，最有效的干扰素诱导剂是单-和二氟苯基类似物。这些相同的类似物也是针对Semliki Forest病毒和1型单纯疱疹的有效抗病毒剂。此外，单甲氧基苯基类似物是有效的抗病毒剂，但是弱干扰素诱导剂。相对适度的结构变化导致生物活性发生巨大变化。循环干扰素水平与全身抗病毒活性之间的相关性相对较差。
• As-Indacen Derivatives
  申请人：Lietzau Lars

  公开号：US20070228328A1

  公开（公告）日：2007-10-04

  The present invention relates to compounds of the formula I where X 1 , X 2 , R 1 , R 2 , A 1 , A 2 , Z 1 , Z 2 , m, n and rings B and B′ are as defined in claim 1.

  本发明涉及公式I的化合物，其中X1、X2、R1、R2、A1、A2、Z1、Z2、m、n和环B和B'的定义如权利要求书中所述。
• Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators
  申请人：Rice Kenneth D.

  公开号：US20100130488A1

  公开（公告）日：2010-05-27

  A compound according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 6 , R 7 and Z are as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof.

  公式（I）所示的化合物或其药学上可接受的盐，其中R1、R2、R6、R7和Z如规范中定义；其制药组合物；以及使用方法。
• Calpain modulators and therapeutic uses thereof
  申请人：Blade Therapeutics, Inc.

  公开号：US10934261B2

  公开（公告）日：2021-03-02

  Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

  本文公开了小分子钙蛋白酶调节剂组合物、药物组合物及其用途和制备方法。
• SKULNICK, H. I.;WEED, S. D.;EIDSON, E. E.;RENIS, H. E.;WIERENGA, W.;STRIN+, J. MED. CHEM., 1985, 28, N 12, 1864-1869
  作者：SKULNICK, H. I.、WEED, S. D.、EIDSON, E. E.、RENIS, H. E.、WIERENGA, W.、STRIN+

  DOI：——

  日期：——